Dr. Rugo on the Optimal Setting for Biosimilar Evaluation
November 20th 2018Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the optimal setting for biosimilar evaluation.
Read More
Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer
November 14th 2018Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses resistance to CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.
Read More
Dr. Rugo Discusses the Equivalency of Trastuzumab Biosimilars
November 3rd 2018Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the equivalency that has been demonstrated with biosimilars for trastuzumab (Herceptin).
Read More
Dr. Rugo Discusses a Comparative Review of Trastuzumab Biosimilars
October 27th 2018Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses a comparative review of trastuzumab (Herceptin) biosimilars.
Read More
Dr. Rugo Discusses Late Recurrence in HR+ Breast Cancer
October 31st 2017Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.
Read More
Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
October 14th 2016Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.
Read More